Arrhythmias & electrophysiology
Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation in Cardiac Amyloidosis
Authors' conclusion
Catheter ablation for AF in patients with cardiac amyloidosis is associated with improved outcomes in all-cause mortality and hospitalization compared to AAD therapy.
Study context
- Population
- Adults (≥18 years) with atrial fibrillation (AF) and cardiac amyloidosis, TriNetX network, 2013–2021118 per group after matching
- Participants
- 120 vs 4,749
- Exposure
- Catheter ablation vs AAD therapy
- Catheter ablationn = 120
- AADn = 4,749reference
- Outcome
- All-cause mortality and cardiac adverse events
- Follow-up
- 3 years
Methodological detailspropensity-score matched, multinational
- Propensity-score matched
- Multinational
Main finding
As reported in the abstract
Catheter ablation vs AADOdds ratio (95% CI)
All-cause mortality
0.404(0.182–0.896)
All-cause hospitalization
0.547(0.317–0.942)
- No significant difference between the 2 groups in cerebrovascular attack
- OR: 1; 95% CI: 0.400-2.500
- No significant difference between the 2 groups in cardiac arrest
- OR: 1; 95% CI: 0.400-2.500
- No significant difference between the 2 groups in acute HF
- OR: 0.688; 95% CI: 0.293-1.617
Observational data: associations, not effects.
Original publication
Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation in Cardiac Amyloidosis. JACC Clin Electrophysiol. Published 7 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →